As has been the case so many times since February, the buyers stepped up to the plate at the last minute to bring the market back from the edge of the cliff. Today’s bounce catalyst was a measurable progress on the employment front. The nation’s unemployment rate fell from 5.5% to 5.4% last month, sending the S&P 500 higher by a hefty 1.35%. The close of 2116.10, however, is still below the pivotal technical ceiling of 2118.

Meanwhile, several stocks completely missed out on the market’s rally. Cerner Corporation (NASDAQ:CERN), Monster Beverage Corp (NASDAQ:MNST) and MannKind Corporation (NASDAQ:MNKD) were three noteworthy names that managed to lose a lot of ground on an otherwise bullish day. Here’s why.

Monster Beverage (MNST)

Falling short of earnings estimates certainly didn’t help matters any, but it may not have been the bulk of the reason MNST stock fell 10% on Friday.

Despite the 17% increase in year-over-year revenue, profits of 62 cents per share missed estimates of 68 cents for the company’s first quarter of the year.

Yes, GAAP earnings fell a stunning 95%, to three cents per share of MNST, but that’s almost entirely attributable to an accounting charge related to a switch in distributors. Most observers and analysts understood it was going to happen, and broadly understood the forecasted profit of 68 cents was mostly a best guess regarding the charge.

So why did MNST still tumble as it did? It’s likely the downgrade from Goldman Sachs, which lowered its opinion on Monster Beverage from a “buy” to a “neutral” rating. Goldman Sachs analysts Judy Hong and Freda Zhuo wrote:

“We see MNST as having best-in-class sales growth, margin upside from Int’l profit ramp-up, compelling ROIC and potential for significant cash return to shareholders (we estimate $2bn of accelerated share repurchase in 2H15 once the KO deal closes). That said, we are mindful of valuation with MNST currently trading at 43.0X, at the very high-end of consumer/retail peer growth peers. Key risks include category growth, market share and distribution transition.”

MannKind Corporation (MNKD)

Whether or not MannKind Corporation topped estimates last quarter is largely a matter of perspective. The loss of eight cents per share of MNKD was in line with some estimates, and actually topped others. Though the company didn’t offer an official revenue number for its first quarter, it did confirm it booked $7.1 million worth of AFREZZA shipments as deferred product sales, which could arguably substitute for sales, which would have topped estimates.

It’s not the Q1 numbers, however, that sent MNKD shares more than 5% lower on Friday. It was the lack of visibility and guidance. While most of the market understands it’s a new enterprise and any guidance is only offered on a best-guess basis, the company’s management seems oddly unconcerned about the slow launch and growing debt.

Investors may be increasingly concerned that not everything is as hunky-dory as was once believed.

Cerner Corporation (CERN)

Healthcare IT company Cerner Corporation was good last quarter…really good. It just wasn’t good enough. The market sent shares down 4.5% as punishment.

When all was said and done, CERN stock earned 45 cents per share last quarter on $996.1 million in revenue. Both were better than year-ago numbers of 37 cents and $784.8 million, respectively. While income of 45 cents per share was on target, sales came up short of the company’s guidance of $1.05 billion to $1.1 billion for Q1.

It was guidance for the current quarter that may have spurred most of today’s near-5% selloff from CERN shares, though. Cerner says it’s looking for a profit of between 51 cents and 52 cents per share in the second quarter, while analysts were expecting an average of 52 cents per share of CERN. The company also foresees revenue of between $1.175 billion and $1.225 billion for Q2, but analysts had been modeling a top line of $1.24 billion.

As of this writing, James Brumley did not hold a position in any of the aforementioned securities.